 | • レポートコード：MRC2-11QY12584 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は悪性中皮腫のグローバル市場について調査・分析したレポートです。種類別（経口、非経口）市場規模、用途別（病院薬局、小売薬局、腫瘍センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別悪性中皮腫の競争状況、市場シェア ・世界の悪性中皮腫市場：種類別市場規模 2015年-2020年（経口、非経口） ・世界の悪性中皮腫市場：種類別市場規模予測 2021年-2026年（経口、非経口） ・世界の悪性中皮腫市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、腫瘍センター、その他） ・世界の悪性中皮腫市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、腫瘍センター、その他） ・北米の悪性中皮腫市場分析：米国、カナダ ・ヨーロッパの悪性中皮腫市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの悪性中皮腫市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の悪性中皮腫市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの悪性中皮腫市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、Bristol-Myers Squibb、Roche、Merck、Novartis、Pfizer、Sanofi、Eli Lilly、Teva Pharmaceuticals、Boehringer Ingelheim GmbH、Mylan、Fresenius Kabi、Sun Pharmaceuticals、Corden Pharma、Concordia International、Kyowa Hakko Kirin、Polaris Pharmaceuticals、MolMed、Ono Pharmaceutical、Nichi-Iko Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.
Market Analysis and Insights: Global Malignant Mesothelioma Market
The global Malignant Mesothelioma market size is projected to reach US$ 448.4 million by 2026, from US$ 420.6 million in 2020, at a CAGR of 6.0%% during 2021-2026.
Global Malignant Mesothelioma Scope and Market Size
Malignant Mesothelioma market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Mesothelioma market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
AstraZeneca
Bristol-Myers Squibb
Roche
Merck
Novartis
Pfizer
Sanofi
Eli Lilly
Teva Pharmaceuticals
Boehringer Ingelheim GmbH
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Corden Pharma
Concordia International
Kyowa Hakko Kirin
Polaris Pharmaceuticals
MolMed
Ono Pharmaceutical
Nichi-Iko Pharmaceutical
Market segment by Type, the product can be split into
Oral
Parenteral
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Oncology Centers
Other
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Malignant Mesothelioma Revenue
1.4 Market by Type
1.4.1 Global Malignant Mesothelioma Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Oral
1.4.3 Parenteral
1.5 Market by Application
1.5.1 Global Malignant Mesothelioma Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Oncology Centers
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Malignant Mesothelioma Market Perspective (2015-2026)
2.2 Global Malignant Mesothelioma Growth Trends by Regions
2.2.1 Malignant Mesothelioma Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Malignant Mesothelioma Historic Market Share by Regions (2015-2020)
2.2.3 Malignant Mesothelioma Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Malignant Mesothelioma Market Growth Strategy
2.3.6 Primary Interviews with Key Malignant Mesothelioma Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Malignant Mesothelioma Players by Market Size
3.1.1 Global Top Malignant Mesothelioma Players by Revenue (2015-2020)
3.1.2 Global Malignant Mesothelioma Revenue Market Share by Players (2015-2020)
3.1.3 Global Malignant Mesothelioma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Malignant Mesothelioma Market Concentration Ratio
3.2.1 Global Malignant Mesothelioma Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Revenue in 2019
3.3 Malignant Mesothelioma Key Players Head office and Area Served
3.4 Key Players Malignant Mesothelioma Product Solution and Service
3.5 Date of Enter into Malignant Mesothelioma Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Malignant Mesothelioma Historic Market Size by Type (2015-2020)
4.2 Global Malignant Mesothelioma Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Malignant Mesothelioma Market Size by Application (2015-2020)
5.2 Global Malignant Mesothelioma Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Malignant Mesothelioma Market Size (2015-2020)
6.2 Malignant Mesothelioma Key Players in North America (2019-2020)
6.3 North America Malignant Mesothelioma Market Size by Type (2015-2020)
6.4 North America Malignant Mesothelioma Market Size by Application (2015-2020)
7 Europe
7.1 Europe Malignant Mesothelioma Market Size (2015-2020)
7.2 Malignant Mesothelioma Key Players in Europe (2019-2020)
7.3 Europe Malignant Mesothelioma Market Size by Type (2015-2020)
7.4 Europe Malignant Mesothelioma Market Size by Application (2015-2020)
8 China
8.1 China Malignant Mesothelioma Market Size (2015-2020)
8.2 Malignant Mesothelioma Key Players in China (2019-2020)
8.3 China Malignant Mesothelioma Market Size by Type (2015-2020)
8.4 China Malignant Mesothelioma Market Size by Application (2015-2020)
9 Japan
9.1 Japan Malignant Mesothelioma Market Size (2015-2020)
9.2 Malignant Mesothelioma Key Players in Japan (2019-2020)
9.3 Japan Malignant Mesothelioma Market Size by Type (2015-2020)
9.4 Japan Malignant Mesothelioma Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Malignant Mesothelioma Market Size (2015-2020)
10.2 Malignant Mesothelioma Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Malignant Mesothelioma Market Size by Type (2015-2020)
10.4 Southeast Asia Malignant Mesothelioma Market Size by Application (2015-2020)
11 India
11.1 India Malignant Mesothelioma Market Size (2015-2020)
11.2 Malignant Mesothelioma Key Players in India (2019-2020)
11.3 India Malignant Mesothelioma Market Size by Type (2015-2020)
11.4 India Malignant Mesothelioma Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Malignant Mesothelioma Market Size (2015-2020)
12.2 Malignant Mesothelioma Key Players in Central & South America (2019-2020)
12.3 Central & South America Malignant Mesothelioma Market Size by Type (2015-2020)
12.4 Central & South America Malignant Mesothelioma Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview
13.1.3 AstraZeneca Malignant Mesothelioma Introduction
13.1.4 AstraZeneca Revenue in Malignant Mesothelioma Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Details
13.2.2 Bristol-Myers Squibb Business Overview
13.2.3 Bristol-Myers Squibb Malignant Mesothelioma Introduction
13.2.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Business (2015-2020)
13.2.5 Bristol-Myers Squibb Recent Development
13.3 Roche
13.3.1 Roche Company Details
13.3.2 Roche Business Overview
13.3.3 Roche Malignant Mesothelioma Introduction
13.3.4 Roche Revenue in Malignant Mesothelioma Business (2015-2020)
13.3.5 Roche Recent Development
13.4 Merck
13.4.1 Merck Company Details
13.4.2 Merck Business Overview
13.4.3 Merck Malignant Mesothelioma Introduction
13.4.4 Merck Revenue in Malignant Mesothelioma Business (2015-2020)
13.4.5 Merck Recent Development
13.5 Novartis
13.5.1 Novartis Company Details
13.5.2 Novartis Business Overview
13.5.3 Novartis Malignant Mesothelioma Introduction
13.5.4 Novartis Revenue in Malignant Mesothelioma Business (2015-2020)
13.5.5 Novartis Recent Development
13.6 Pfizer
13.6.1 Pfizer Company Details
13.6.2 Pfizer Business Overview
13.6.3 Pfizer Malignant Mesothelioma Introduction
13.6.4 Pfizer Revenue in Malignant Mesothelioma Business (2015-2020)
13.6.5 Pfizer Recent Development
13.7 Sanofi
13.7.1 Sanofi Company Details
13.7.2 Sanofi Business Overview
13.7.3 Sanofi Malignant Mesothelioma Introduction
13.7.4 Sanofi Revenue in Malignant Mesothelioma Business (2015-2020)
13.7.5 Sanofi Recent Development
13.8 Eli Lilly
13.8.1 Eli Lilly Company Details
13.8.2 Eli Lilly Business Overview
13.8.3 Eli Lilly Malignant Mesothelioma Introduction
13.8.4 Eli Lilly Revenue in Malignant Mesothelioma Business (2015-2020)
13.8.5 Eli Lilly Recent Development
13.9 Teva Pharmaceuticals
13.9.1 Teva Pharmaceuticals Company Details
13.9.2 Teva Pharmaceuticals Business Overview
13.9.3 Teva Pharmaceuticals Malignant Mesothelioma Introduction
13.9.4 Teva Pharmaceuticals Revenue in Malignant Mesothelioma Business (2015-2020)
13.9.5 Teva Pharmaceuticals Recent Development
13.10 Boehringer Ingelheim GmbH
13.10.1 Boehringer Ingelheim GmbH Company Details
13.10.2 Boehringer Ingelheim GmbH Business Overview
13.10.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Introduction
13.10.4 Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Business (2015-2020)
13.10.5 Boehringer Ingelheim GmbH Recent Development
13.11 Mylan
10.11.1 Mylan Company Details
10.11.2 Mylan Business Overview
10.11.3 Mylan Malignant Mesothelioma Introduction
10.11.4 Mylan Revenue in Malignant Mesothelioma Business (2015-2020)
10.11.5 Mylan Recent Development
13.12 Fresenius Kabi
10.12.1 Fresenius Kabi Company Details
10.12.2 Fresenius Kabi Business Overview
10.12.3 Fresenius Kabi Malignant Mesothelioma Introduction
10.12.4 Fresenius Kabi Revenue in Malignant Mesothelioma Business (2015-2020)
10.12.5 Fresenius Kabi Recent Development
13.13 Sun Pharmaceuticals
10.13.1 Sun Pharmaceuticals Company Details
10.13.2 Sun Pharmaceuticals Business Overview
10.13.3 Sun Pharmaceuticals Malignant Mesothelioma Introduction
10.13.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Business (2015-2020)
10.13.5 Sun Pharmaceuticals Recent Development
13.14 Corden Pharma
10.14.1 Corden Pharma Company Details
10.14.2 Corden Pharma Business Overview
10.14.3 Corden Pharma Malignant Mesothelioma Introduction
10.14.4 Corden Pharma Revenue in Malignant Mesothelioma Business (2015-2020)
10.14.5 Corden Pharma Recent Development
13.15 Concordia International
10.15.1 Concordia International Company Details
10.15.2 Concordia International Business Overview
10.15.3 Concordia International Malignant Mesothelioma Introduction
10.15.4 Concordia International Revenue in Malignant Mesothelioma Business (2015-2020)
10.15.5 Concordia International Recent Development
13.16 Kyowa Hakko Kirin
10.16.1 Kyowa Hakko Kirin Company Details
10.16.2 Kyowa Hakko Kirin Business Overview
10.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Introduction
10.16.4 Kyowa Hakko Kirin Revenue in Malignant Mesothelioma Business (2015-2020)
10.16.5 Kyowa Hakko Kirin Recent Development
13.17 Polaris Pharmaceuticals
10.17.1 Polaris Pharmaceuticals Company Details
10.17.2 Polaris Pharmaceuticals Business Overview
10.17.3 Polaris Pharmaceuticals Malignant Mesothelioma Introduction
10.17.4 Polaris Pharmaceuticals Revenue in Malignant Mesothelioma Business (2015-2020)
10.17.5 Polaris Pharmaceuticals Recent Development
13.18 MolMed
10.18.1 MolMed Company Details
10.18.2 MolMed Business Overview
10.18.3 MolMed Malignant Mesothelioma Introduction
10.18.4 MolMed Revenue in Malignant Mesothelioma Business (2015-2020)
10.18.5 MolMed Recent Development
13.19 Ono Pharmaceutical
10.19.1 Ono Pharmaceutical Company Details
10.19.2 Ono Pharmaceutical Business Overview
10.19.3 Ono Pharmaceutical Malignant Mesothelioma Introduction
10.19.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Business (2015-2020)
10.19.5 Ono Pharmaceutical Recent Development
13.20 Nichi-Iko Pharmaceutical
10.20.1 Nichi-Iko Pharmaceutical Company Details
10.20.2 Nichi-Iko Pharmaceutical Business Overview
10.20.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Introduction
10.20.4 Nichi-Iko Pharmaceutical Revenue in Malignant Mesothelioma Business (2015-2020)
10.20.5 Nichi-Iko Pharmaceutical Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Malignant Mesothelioma Key Market Segments
Table 2. Key Players Covered: Ranking by Malignant Mesothelioma Revenue
Table 3. Ranking of Global Top Malignant Mesothelioma Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Malignant Mesothelioma Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Oral
Table 6. Key Players of Parenteral
Table 7. Global Malignant Mesothelioma Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Malignant Mesothelioma Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Malignant Mesothelioma Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Malignant Mesothelioma Market Share by Regions (2015-2020)
Table 11. Global Malignant Mesothelioma Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Malignant Mesothelioma Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Malignant Mesothelioma Market Growth Strategy
Table 17. Main Points Interviewed from Key Malignant Mesothelioma Players
Table 18. Global Malignant Mesothelioma Revenue by Players (2015-2020) (Million US$)
Table 19. Global Malignant Mesothelioma Market Share by Players (2015-2020)
Table 20. Global Top Malignant Mesothelioma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Mesothelioma as of 2019)
Table 21. Global Malignant Mesothelioma by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Malignant Mesothelioma Product Solution and Service
Table 24. Date of Enter into Malignant Mesothelioma Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Malignant Mesothelioma Market Size by Type (2015-2020) (Million US$)
Table 27. Global Malignant Mesothelioma Market Size Share by Type (2015-2020)
Table 28. Global Malignant Mesothelioma Revenue Market Share by Type (2021-2026)
Table 29. Global Malignant Mesothelioma Market Size Share by Application (2015-2020)
Table 30. Global Malignant Mesothelioma Market Size by Application (2015-2020) (Million US$)
Table 31. Global Malignant Mesothelioma Market Size Share by Application (2021-2026)
Table 32. North America Key Players Malignant Mesothelioma Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Malignant Mesothelioma Market Share (2019-2020)
Table 34. North America Malignant Mesothelioma Market Size by Type (2015-2020) (Million US$)
Table 35. North America Malignant Mesothelioma Market Share by Type (2015-2020)
Table 36. North America Malignant Mesothelioma Market Size by Application (2015-2020) (Million US$)
Table 37. North America Malignant Mesothelioma Market Share by Application (2015-2020)
Table 38. Europe Key Players Malignant Mesothelioma Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Malignant Mesothelioma Market Share (2019-2020)
Table 40. Europe Malignant Mesothelioma Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Malignant Mesothelioma Market Share by Type (2015-2020)
Table 42. Europe Malignant Mesothelioma Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Malignant Mesothelioma Market Share by Application (2015-2020)
Table 44. China Key Players Malignant Mesothelioma Revenue (2019-2020) (Million US$)
Table 45. China Key Players Malignant Mesothelioma Market Share (2019-2020)
Table 46. China Malignant Mesothelioma Market Size by Type (2015-2020) (Million US$)
Table 47. China Malignant Mesothelioma Market Share by Type (2015-2020)
Table 48. China Malignant Mesothelioma Market Size by Application (2015-2020) (Million US$)
Table 49. China Malignant Mesothelioma Market Share by Application (2015-2020)
Table 50. Japan Key Players Malignant Mesothelioma Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Malignant Mesothelioma Market Share (2019-2020)
Table 52. Japan Malignant Mesothelioma Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Malignant Mesothelioma Market Share by Type (2015-2020)
Table 54. Japan Malignant Mesothelioma Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Malignant Mesothelioma Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Malignant Mesothelioma Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Malignant Mesothelioma Market Share (2019-2020)
Table 58. Southeast Asia Malignant Mesothelioma Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Malignant Mesothelioma Market Share by Type (2015-2020)
Table 60. Southeast Asia Malignant Mesothelioma Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Malignant Mesothelioma Market Share by Application (2015-2020)
Table 62. India Key Players Malignant Mesothelioma Revenue (2019-2020) (Million US$)
Table 63. India Key Players Malignant Mesothelioma Market Share (2019-2020)
Table 64. India Malignant Mesothelioma Market Size by Type (2015-2020) (Million US$)
Table 65. India Malignant Mesothelioma Market Share by Type (2015-2020)
Table 66. India Malignant Mesothelioma Market Size by Application (2015-2020) (Million US$)
Table 67. India Malignant Mesothelioma Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Malignant Mesothelioma Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Malignant Mesothelioma Market Share (2019-2020)
Table 70. Central & South America Malignant Mesothelioma Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Malignant Mesothelioma Market Share by Type (2015-2020)
Table 72. Central & South America Malignant Mesothelioma Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Malignant Mesothelioma Market Share by Application (2015-2020)
Table 74. AstraZeneca Company Details
Table 75. AstraZeneca Business Overview
Table 76. AstraZeneca Product
Table 77. AstraZeneca Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 78. AstraZeneca Recent Development
Table 79. Bristol-Myers Squibb Company Details
Table 80. Bristol-Myers Squibb Business Overview
Table 81. Bristol-Myers Squibb Product
Table 82. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 83. Bristol-Myers Squibb Recent Development
Table 84. Roche Company Details
Table 85. Roche Business Overview
Table 86. Roche Product
Table 87. Roche Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 88. Roche Recent Development
Table 89. Merck Company Details
Table 90. Merck Business Overview
Table 91. Merck Product
Table 92. Merck Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 93. Merck Recent Development
Table 94. Novartis Company Details
Table 95. Novartis Business Overview
Table 96. Novartis Product
Table 97. Novartis Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 98. Novartis Recent Development
Table 99. Pfizer Company Details
Table 100. Pfizer Business Overview
Table 101. Pfizer Product
Table 102. Pfizer Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 103. Pfizer Recent Development
Table 104. Sanofi Company Details
Table 105. Sanofi Business Overview
Table 106. Sanofi Product
Table 107. Sanofi Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 108. Sanofi Recent Development
Table 109. Eli Lilly Business Overview
Table 110. Eli Lilly Product
Table 111. Eli Lilly Company Details
Table 112. Eli Lilly Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 113. Eli Lilly Recent Development
Table 114. Teva Pharmaceuticals Company Details
Table 115. Teva Pharmaceuticals Business Overview
Table 116. Teva Pharmaceuticals Product
Table 117. Teva Pharmaceuticals Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 118. Teva Pharmaceuticals Recent Development
Table 119. Boehringer Ingelheim GmbH Company Details
Table 120. Boehringer Ingelheim GmbH Business Overview
Table 121. Boehringer Ingelheim GmbH Product
Table 122. Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 123. Boehringer Ingelheim GmbH Recent Development
Table 124. Mylan Company Details
Table 125. Mylan Business Overview
Table 126. Mylan Product
Table 127. Mylan Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 128. Mylan Recent Development
Table 129. Fresenius Kabi Company Details
Table 130. Fresenius Kabi Business Overview
Table 131. Fresenius Kabi Product
Table 132. Fresenius Kabi Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 133. Fresenius Kabi Recent Development
Table 134. Sun Pharmaceuticals Company Details
Table 135. Sun Pharmaceuticals Business Overview
Table 136. Sun Pharmaceuticals Product
Table 137. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 138. Sun Pharmaceuticals Recent Development
Table 139. Corden Pharma Company Details
Table 140. Corden Pharma Business Overview
Table 141. Corden Pharma Product
Table 142. Corden Pharma Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 143. Corden Pharma Recent Development
Table 144. Concordia International Company Details
Table 145. Concordia International Business Overview
Table 146. Concordia International Product
Table 147. Concordia International Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 148. Concordia International Recent Development
Table 149. Kyowa Hakko Kirin Company Details
Table 150. Kyowa Hakko Kirin Business Overview
Table 151. Kyowa Hakko Kirin Product
Table 152. Kyowa Hakko Kirin Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 153. Kyowa Hakko Kirin Recent Development
Table 154. Polaris Pharmaceuticals Company Details
Table 155. Polaris Pharmaceuticals Business Overview
Table 156. Polaris Pharmaceuticals Product
Table 157. Polaris Pharmaceuticals Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 158. Polaris Pharmaceuticals Recent Development
Table 159. MolMed Company Details
Table 160. MolMed Business Overview
Table 161. MolMed Product
Table 162. MolMed Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 163. MolMed Recent Development
Table 164. Ono Pharmaceutical Company Details
Table 165. Ono Pharmaceutical Business Overview
Table 166. Ono Pharmaceutical Product
Table 167. Ono Pharmaceutical Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 168. Ono Pharmaceutical Recent Development
Table 169. Nichi-Iko Pharmaceutical Company Details
Table 170. Nichi-Iko Pharmaceutical Business Overview
Table 171. Nichi-Iko Pharmaceutical Product
Table 172. Nichi-Iko Pharmaceutical Revenue in Malignant Mesothelioma Business (2015-2020) (Million US$)
Table 173. Nichi-Iko Pharmaceutical Recent Development
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Mesothelioma Market Share by Type: 2020 VS 2026
Figure 2. Oral Features
Figure 3. Parenteral Features
Figure 4. Global Malignant Mesothelioma Market Share by Application: 2020 VS 2026
Figure 5. Hospital Pharmacies Case Studies
Figure 6. Retail Pharmacies Case Studies
Figure 7. Oncology Centers Case Studies
Figure 8. Other Case Studies
Figure 9. Malignant Mesothelioma Report Years Considered
Figure 10. Global Malignant Mesothelioma Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Malignant Mesothelioma Market Share by Regions: 2020 VS 2026
Figure 12. Global Malignant Mesothelioma Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Malignant Mesothelioma Market Share by Players in 2019
Figure 15. Global Top Malignant Mesothelioma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Mesothelioma as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Revenue in 2019
Figure 17. North America Malignant Mesothelioma Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Malignant Mesothelioma Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Malignant Mesothelioma Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Malignant Mesothelioma Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Malignant Mesothelioma Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Malignant Mesothelioma Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Malignant Mesothelioma Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
悪性中皮腫治療薬の世界市場（～2026年） Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the foreca…- 悪性中皮腫治療の世界市場（～2026年） Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is…
- 悪性リンパ腫の世界市場（～2026年） Cancers that start anywhere in the body’s lymphatic system are called lymphomas. If they have the ability to spread, they are called malignant. The lymphatic system runs throughout our bodies and is composed of lymphoid tissue, vessels, and fluid. Lymphoid tissue contains lymph nodes, which are part…
- 悪性神経膠腫の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…
- 悪性神経膠腫治療の世界市場（～2026年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…